Celgene price target raised to $114 from $104 at Jefferies Jefferies raised its price target for Celgene to reflect the addition of modest apremilast expectations and Abraxane penetration in pancreatic cancer. The firm keeps a Buy rating on the stock.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.